Chronic pain is a multifaceted and complex condition. Broadly classified into somatic, visceral, or neuropathic pain, it is poorly managed despite its prevalence. Current drugs used for the treatment of chronic pain are limited by tolerance with longterm use, abuse potential, and multiple adverse side effects. The persistent nature of pain suggests that epigenetic machinery may be a critical factor driving chronic pain. In this review, we discuss the latest insights into epigenetic processes, including DNA methylation, histone modifications, and microRNAs, and we describe their involvement in the pathophysiology of chronic pain and whether epigenetic modifications could be applied as future therapeutic targets for chronic pain. We provide evidence from experimental models and translational research in human tissue that have enhanced our understanding of epigenetic processes mediating nociception, and we then speculate on the potential future use of more specific and selective agents that target epigenetic mechanisms to attenuate pain.
Ligon, C. O., Moloney, R. D., & Greenwood-Van Meerveld, B. (2016, April 1). Targeting epigenetic mechanisms for chronic pain: A valid approach for the development of novel therapeutics. Journal of Pharmacology and Experimental Therapeutics. American Society for Pharmacology and Experimental Therapy. https://doi.org/10.1124/jpet.115.231670